TRIPLE NEGATIVE BREAST CANCER

This study tests a personalized vaccine made from a patient's own leftover tumor after chemotherapy and surgery. The goal is to see if the vaccine is safe and can train the immune system to fight any remaining cancer cells. The trial enrolls 16 people with high-risk triple negati…

This study tests an experimental vaccine made from a patient's own immune cells (dendritic cells) that are trained to recognize HER2 and HER3 proteins. The vaccine is injected directly into the tumor along with standard chemotherapy before surgery. The goal is to see if this comb…

This study tests a new cancer vaccine called Modi-1 in 168 people with advanced breast, head & neck, ovarian, or kidney cancer. The vaccine is designed to help the immune system recognize and attack cancer cells. Some participants will receive the vaccine alone, while others will…

This study tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer that has not responded to prior treatments. The goal is to see if the new dosing is safer and works better at shrinking tumors or slowing cancer…

This study tests a new drug called SKB264 against standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. The trial includes 524 adults whose tumors do not have a certain protein (PD-L1) or who have al…

This study tests a new drug, APL-5125, in about 100 adults with advanced solid tumors like colorectal, pancreatic, and breast cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The trial has two pha…

This study is for people with low-risk, early-stage triple-negative breast cancer. It compares two treatments: one drug alone versus that drug plus an immunotherapy. The goal is to see which approach leads to a complete disappearance of cancer before surgery. About 348 participan…

This study tests whether adding two drugs (sacituzumab govitecan and zimberelimab) to targeted brain radiation can help people with a tough-to-treat type of breast cancer that has spread to the brain. About 31 adults with triple negative breast cancer and brain metastases will ta…

This study tests a specific chemotherapy combination (epirubicin/cyclophosphamide followed by docetaxel/carboplatin) in 85 Nigerian women with triple-negative breast cancer. The goal is to see how many have no cancer left in the breast or lymph nodes after treatment. Researchers …

This early-phase study tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goals are to find the safest dose and understan…

This early-stage study tests a new treatment for triple-negative breast cancer that has come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is …

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to an existing immunotherapy (atezolizumab) can help control several advanced solid tumors, including pancreatic, lung, bladder, and triple-negative breast cancer. About 247 adults with t…

This study tests a new treatment called NECVAX-NEO1 for people with triple-negative breast cancer, a tough-to-treat type. It is given alongside standard chemotherapy and immunotherapy before and after surgery. The goal is to see if it is safe and helps control the disease better.…

This early-phase trial tests a personalized cell therapy for people with advanced triple negative breast cancer that has stopped responding to standard treatments. Doctors take a patient's own immune cells, train them in the lab to recognize and attack cancer cells, and return th…

This study looks at whether a structured nutrition and exercise program can help women with triple-negative breast cancer achieve a complete response—meaning no cancer remains in the breast—after chemo-immunotherapy before surgery. The trial enrolls 160 women who are not currentl…

This study tests a new drug called LBL-024, alone or with chemotherapy, in people whose triple negative breast cancer has come back or spread. The goal is to see if it can shrink tumors and control the disease. About 220 adults with this aggressive cancer type will take part.

This study tests two different chemotherapy drug combinations in people with advanced triple-negative breast cancer, a fast-growing type. About 414 participants will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus capecitabine. The goal is to see which combi…

This study tests a new drug called JSKN016 against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The goal is to see if JSKN016 can slow cancer growth or extend survival. About 364 adults aged 18 …

This study tests whether a combination of several drugs can help treat a type of breast cancer (triple-negative) that has stopped responding to standard immunotherapy. About 80 adults with advanced cancer will receive one of seven different drug mixes. The goal is to see if the t…

This early-stage study tests a new oral medication, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The goal is to find the safest dose and see if it works alone or with other cancer treatments. About 260 adults will take the pill daily in 28-day…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests whether giving a combination of three drugs (nab-paclitaxel, carboplatin, and Camrelizumab) before surgery can eliminate all signs of cancer in people with early-stage triple-negative breast cancer. About 64 participants will receive the treatment and then have s…

This study tests whether combining the immunotherapy drug pembrolizumab with two chemotherapy drugs (carboplatin and paclitaxel) can shrink tumors before surgery in people with stage 1 triple-negative breast cancer. About 28 participants will receive the treatment and then be mon…

This study tests whether adding the experimental drug sacituzumab govitecan to the immunotherapy pembrolizumab works better than standard treatments for people with triple negative breast cancer that still remains after surgery and pre-surgery therapy. About 1,500 participants wi…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 part…

This study tests a 12-18 week treatment using carboplatin, paclitaxel, and pembrolizumab for people with triple-negative breast cancer who cannot take standard heart-damaging chemotherapy due to existing heart conditions or high risk. The goal is to see if this heart-safe combina…

This study tests whether giving high-precision radiation (SBRT) to all visible cancer spots can delay the disease from getting worse in people with 1 to 5 metastases from breast or lung cancer. About 145 participants will be randomly assigned to receive either standard care alone…

This study tests whether matching treatment to the specific molecular subtype of triple-negative breast cancer can shrink tumors or slow their growth. It involves 120 women whose cancer has not responded to standard therapies. Researchers will measure how many participants achiev…

This early-phase study tests an experimental oral drug called ATX-295 in about 90 adults with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also …

This study tests two different chemotherapy combinations (nab-paclitaxel plus carboplatin vs. nab-paclitaxel plus epirubicin) given before surgery to shrink tumors in people with triple-negative breast cancer. The goal is to see which combo works better at eliminating cancer cell…

This early-phase trial tests a new drug called bulumtatug furvedotin (BFv) in people with triple-negative breast cancer that has returned or spread and who have already tried certain other treatments. The study aims to see if the drug can shrink tumors or stop them from growing. …

This study tests whether an early PET scan can help doctors personalize chemotherapy and immunotherapy for people with stage 2 or 3 triple negative breast cancer. About 30 participants will receive a combination of drugs, and those whose tumors shrink quickly may avoid extra chem…

This study tests whether adding durvalumab to datopotamab deruxtecan works better than datopotamab deruxtecan alone for people with PDL1-negative metastatic triple-negative breast cancer, a type that doesn't respond to standard immunotherapy. About 140 women will be randomly assi…

This early-phase study tests a new treatment called PeptiCRAd-1, a virus designed to train the immune system to attack cancer cells, combined with the immunotherapy drug pembrolizumab. About 15 adults with certain advanced solid tumors (like melanoma, lung cancer, or sarcoma) wil…

This early-phase study tests a new drug called AZD6750, which is designed to guide the immune system to attack cancer cells. It is for adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that have not responded to other treatments. The study will check …

This study tests whether adding tetrathiomolybdate (TM) to standard capecitabine can lower the chance of breast cancer returning in patients with high-risk triple-negative breast cancer. About 204 participants who have completed initial treatment and surgery will receive either T…

This early-phase study tests a new investigational drug called azirkitug, alone or combined with other drugs, in adults with advanced solid tumors such as lung, head/neck, colorectal, and breast cancers. The main goals are to check safety, side effects, and how the drug moves thr…

This early-stage study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck,…

This study is testing a new treatment for people with advanced breast cancer that has not responded to standard therapies. The treatment uses specially designed immune cells (CAR-NK cells) that are tailored to attack specific markers on each person's tumor. The goal is to see if …

This study looks at whether some women with early-stage triple-negative breast cancer can safely receive less chemotherapy. It uses a marker called TILs (tumor-infiltrating lymphocytes) to decide who might need only the immunotherapy drug pembrolizumab plus a short course of chem…

This study tests whether adding a new drug (INBRX-106) to an existing immunotherapy (pembrolizumab) can shrink breast tumors before standard treatment. About 12 adults with stage II or III triple-negative breast cancer will receive the combo for two cycles. The goal is to see if …

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study tests a new treatment for people with advanced cancers that have spread and express a protein called NY-ESO-1. Patients receive a single infusion of their own immune cells that have been genetically modified to recognize and attack cancer cells. The goal is to see if t…

This early-stage study tests an experimental pill called CID-078 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 220 adults with cancers like lung, breast…

This early-stage study tests a new drug called IDE034 in about 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink …

This study tests a drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to check safety and see if the drug shrinks tumors. About 764 participants with cancers like ovarian, lung, breast, or endometrial cancer will t…

This early-phase trial tests a new drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific marker (folate receptor alpha). The study has two parts: first, finding a safe dose, and then checking how well that dose …

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find a safe dose and check for side effects. About 319 participants will receive the drug to see…

This study is for people with triple-negative breast cancer that has spread and does not have a protein called PD-L1. It compares a standard chemotherapy-like drug (sacituzumab govitecan) alone versus the same drug combined with an immunotherapy (pembrolizumab). The goal is to se…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune system's response to the drug pembrolizumab in people with advanced triple-negative breast cancer. About 30 participants will either receive the combination or pembrolizumab alone. The goal …

This study tests whether two drugs, sacituzumab govitecan and atezolizumab, can clear leftover cancer cells in the breast or lymph nodes of people with triple negative breast cancer. About 40 participants who still have cancer after standard chemotherapy will receive the combinat…

This study tests whether adding the drug serplulimab to standard chemotherapy before surgery can eliminate all signs of triple-negative breast cancer in 46 women. Participants receive the combination weekly, then have surgery to check if the cancer is gone. The goal is to see if …

This study tests if injecting the drug INT230-6 into breast tumors before standard chemotherapy and immunotherapy can help eliminate all cancer in the breast and lymph nodes. About 61 people with early triple-negative breast cancer (a fast-growing type) will be randomly assigned …

This study tests whether adding the drug VEGFR BP102 to standard chemotherapy can help people with a specific subtype of advanced triple-negative breast cancer (called BLIS) live longer without their cancer growing. About 134 participants who have not had prior treatment for meta…

This study tests a drug called sacituzumab govitecan, given before surgery, in people with localized triple-negative breast cancer. The goal is to see if it can eliminate all signs of cancer in the breast and lymph nodes at the time of surgery. About 260 participants will receive…

This early-stage study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study tests whether adding a new drug (MK-2870) to standard immunotherapy (pembrolizumab) can better prevent breast cancer from returning in people with triple-negative breast cancer who still had tumor cells after initial chemotherapy and surgery. About 1,530 participants w…

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This study looks at whether giving immunotherapy less often (extended dose intervals) works as well as the standard schedule for people with advanced triple-negative breast cancer. The goal is to keep the cancer under control while reducing side effects and improving quality of l…

This phase 3 trial tests whether adding the antibiotic moxifloxacin to standard chemotherapy can help control metastatic triple-negative breast cancer longer than chemo alone. About 228 adults with this aggressive cancer who have not yet received treatment for their advanced dise…

This early-phase trial tests a new drug (ASTX660) combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors, including triple-negative breast cancer and cervical cancer. The goal is to see if the combination is safe and can help the immune system recogni…

This study looks at whether taking vitamin D during chemotherapy can help women with triple negative breast cancer and low vitamin D levels achieve a complete response (no cancer left after treatment). About 50 participants will receive standard chemotherapy plus vitamin D supple…

This study tests an experimental pill, VLS-1488, in people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein that helps cancer cells divide. The trial has two parts: first finding a safe dose, then checking if it shrinks …

This study tests whether adding the drug tocilizumab (used for arthritis) to standard chemotherapy helps shrink tumors or delay cancer growth in people with metastatic triple-negative or estrogen-receptor-low breast cancer. The trial enrolls 168 Black and non-Black adults who hav…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 470 adults will take part.

This phase 3 trial tests whether a combination of three drugs (camrelizumab, apatinib, and eribulin) works better than standard chemotherapy for people with advanced triple-negative breast cancer. The study involves 246 participants and will measure how long the cancer stays unde…

This early-stage study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors, including pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see …

This study tests a combination of three drugs (atezolizumab, vinorelbine, and cyclophosphamide) in people with advanced triple-negative breast cancer that has spread. Participants must have had immunotherapy before. The goal is to see if this combo can shrink tumors and improve s…

This early-phase study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple-negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants with advance…

This study is for people with early-stage triple-negative breast cancer who are scheduled for surgery. Before surgery, they will receive two drugs: lenvatinib (taken daily for 7 days) and one dose of pembrolizumab (given by IV). The goal is to see if this short treatment can incr…

This study is for people with metastatic breast cancer (cancer that has spread). It aims to see if choosing treatments based on specific tumor markers (biomarkers) can help control the disease longer. About 700 participants will receive standard therapies matched to their biomark…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study tests two new drug combinations for people with advanced triple-negative breast cancer that has come back or spread. About 80 adults aged 18-75 who have not had prior treatment for advanced disease will receive either JS207 plus 9MW2821 or JS207 plus albumin paclitaxel…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests a new treatment called A2B395 for adults with advanced solid tumors (like colorectal, lung, breast, and kidney cancers) that have not responded to standard therapy. The treatment uses specially engineered immune cells designed to kill cancer cells while protectin…

This study tests whether adding an antivascular drug to standard chemotherapy helps prevent breast cancer from returning in people with a specific, high-risk type of triple-negative breast cancer. About 764 women with stage II to III cancer will receive either the combination or …

This study tests whether using a tumor's genetic profile to customize radiation doses can better control triple negative breast cancer after lumpectomy. About 86 participants will receive radiation tailored to their individual risk, with the goal of preventing cancer from returni…

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can predict if triple-negative breast cancer will completely respond to chemotherapy plus immunotherapy before surgery. About 60 women with early-stage, high-risk breast cancer will receive the scan before starti…

This study compares a contrast-enhanced digital mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy before surgery. About 30 women with locally advanced breast cancer will get 1-2 of these s…

This study tests whether a medicine called pegfilgrastim can prevent a dangerous drop in white blood cells (febrile neutropenia) in women with triple-negative breast cancer who are receiving a specific chemotherapy regimen. About 40 adult patients will receive pegfilgrastim after…

This study is testing a special PET scan that looks for a marker called PSMA in women with advanced triple negative breast cancer. The goal is to see if this marker shows up on tumors, which could open the door to using targeted radiation therapy in the future. About 30 women wit…

This study looks at whether routine brain MRIs can find cancer that has spread to the brain in people with metastatic or inflammatory breast cancer. About 214 participants will get screening MRIs to see how often brain metastases occur and how they affect quality of life. The goa…

This study looks at how near-complete estrogen deprivation (NCED) therapy, used to treat breast cancer, impacts heart function. Researchers will use heart scans to measure blood flow in 90 women aged 55 or younger who are premenopausal at diagnosis. The goal is to understand if t…

This study is collecting tumor, blood, and plasma samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). The goal is to find new markers that link tumor genetics and immune response to how the disease behaves. Participa…

This study takes small tumor samples from 163 people with early-stage triple-negative breast cancer and grows them in the lab as 3D mini-tumors called organoids. Researchers will test different cancer drugs on these organoids to see which ones work best and look for biological ma…

This study looks at whether combining four types of scans (ultrasound, mammography, MRI, and PET-CT) can accurately predict if triple-negative breast cancer has been completely eliminated by chemotherapy and immunotherapy. Researchers will also check blood markers to identify whi…

This study tests whether a special PET/MRI scan can track how immunotherapy affects triple negative breast cancer. About 20 patients will get the scan before and during their regular treatment, but the scan results won't change their care. The goal is to see if the scan can predi…

This study tests whether a type of whole-body MRI (DWB-MRI) can detect the return or spread of breast cancer earlier than standard scans. Researchers will follow 145 people with high-risk breast cancer (HER2+ or triple-negative) for 5 years to see if early detection leads to bett…

This study is testing whether regular brain MRIs can detect cancer that has spread to the brain in people with stage IV breast cancer who have no brain symptoms. About 170 participants with different breast cancer subtypes will get brain scans at the start and again at 6 months o…

This study is collecting tissue and blood samples from 500 people with breast cancer who are receiving treatment before surgery. Researchers will analyze these samples to learn why some cancers respond well to therapy while others do not. The goal is to find better ways to predic…

This study looks at whether regular blood tests for cancer DNA, followed by a special PET scan if the DNA is found, can help detect the return of triple-negative breast cancer earlier than usual scans. About 450 women who finished treatment for early-stage triple-negative breast …

This study looks at 42 women with triple negative breast cancer, an aggressive type that lacks targeted treatments. Participants will receive standard chemotherapy, and researchers will measure tiny molecules in the blood (microRNAs) to see if they can signal early whether the tr…

This study looks at whether a blood test can find tiny bits of tumor DNA (ctDNA) in people with early-stage triple-negative breast cancer. Researchers will collect blood samples before and during treatment to see if the test can help predict cancer coming back. About 77 participa…

This study is for people with triple-negative breast cancer who still have cancer cells after standard chemotherapy. Researchers will use a simple blood test (liquid biopsy) to look for tumor DNA before and during treatment with the drug capecitabine. The goal is to learn whether…

This study looks at whether a blood test that measures circulating tumor DNA (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. Researchers will take blood samples from 125 women with stage II or III breast cancer before, during, and after tr…

This study looks at whether it is possible and acceptable to take multiple tissue samples (biopsies) from different tumor sites over time in people with metastatic breast cancer. The goal is to understand how the cancer changes and becomes resistant to treatment. Researchers will…

This study looks at bacteria living in breast tumors to see if they can help predict how well chemotherapy and immunotherapy work in people with early-stage triple negative breast cancer. Researchers will collect tissue samples before and after treatment from 30 participants. The…